---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013370"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:47:22.767491+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca reports Phase 1b data for ERAS-601+cetuximab; MTD 40mg BID; tolerable safety

## Summary
- Promising initial safety from Phase 1b FLAGSHP-1 dose escalation for ERAS-601 + cetuximab in advanced solid tumors.
- Only Grade 1-2 TRAEs at or below the combination MTD; ERAS-601 MTD 40 mg BID 3/1 with cetuximab 500 mg/m2 Q2W.
- Data presented at AACR 2023; expects initial Phase 1b dose expansion data in HPV-negative HNSCC in H1 2024.

## SEC filing metadata
- accession: 0000950170-23-013370
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023013370/0000950170-23-013370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023013370/eras-20230418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013370
- JSON: https://secwatch.observer/filing/0000950170-23-013370.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.